KP

Kiniksa Pharmaceuticals

www.kiniksa.com link_icon

Kiniksa Pharmaceuticals Market Research Report





Company Overview



  • Name: Kiniksa Pharmaceuticals

  • Mission: To relentlessly and focusedly put patients at the center of everything to develop life-changing medicines.

  • Founded: 2015

  • Founder(s): No information is available

  • Key People:

  • Sanj K. Patel, CEO & Chairman of the Board

  • Ross Moat, Chief Commercial Officer

  • Maddy Zeylikman, SVP General Counsel

  • Mark Ragosa, Chief Financial Officer

  • Eben Tessari, Chief Operating Officer

  • Martina Struck, SVP Regulatory Affairs

  • John Paolini, Chief Medical Officer

  • Mei Jang, SVP Technical Operations

  • Mike Megna, GVP Finance & Chief Accounting Officer

  • Randy Perrin, GVP Global Medical Affairs

  • Aaron Young, Chief Intellectual Property Officer

  • Joseph Pirrello, Chief Business Officer

  • Jennifer Ring, VP Program & Alliance Management

  • Chad Morin, SVP Chief Compliance Officer

  • Headquarters:

  • USA Headquarters: Kiniksa Pharmaceuticals Corp., 100 Hayden Avenue, Lexington, MA 02421, USA

  • Additional Offices in London, UK, Zug, Switzerland, and San Diego, CA, USA

  • Number of Employees: No information is available

  • Revenue: No information is available

  • Company Specialty: Known for developing novel treatments for patients with significant unmet needs, focusing particularly on immune modulation and the treatment of inflammatory and rare diseases.


Products



ARCALYST (Rilonacept)


  • Description: A therapy used for conditions such as recurrent pericarditis.

  • Key Features:

  • FDA approved for multiple rare conditions.

  • Received Breakthrough Therapy designation for recurrent pericarditis in 2019.

  • Granted Orphan Drug exclusivity in March 2021 for recurrent pericarditis treatment.

  • The European Commission granted Orphan Drug designation for idiopathic pericarditis in 2021.


Mavrilimumab


  • Description: Used in the treatment of rheumatoid arthritis and giant cell arteritis, among other applications.

  • Key Features:

  • Phase 2 clinical trials showed significant statistical achievement in efficacy and safety endpoints.


KPL-404


  • Description: An anti-CD40 monoclonal antibody aimed at autoimmune diseases.

  • Key Features:

  • Demonstrated efficacy, safety, and pharmacokinetics in phase 2 trials involving rheumatoid arthritis.


Recent Developments



  • Conferences and Presentations:

  • Participated in the Jefferies London Healthcare Conference.

  • Various presentations at healthcare conferences, including those focused on rheumatology and cardiovascular diseases.


  • Financial Activity:

  • Released third-quarter financial results for the year 2024, indicating recent company performance.


  • Campaign Partnerships:

  • Partnered with GRAMMY® Award-winning singer-songwriter Carly Pearce to expand the Life DisRPted™ Campaign, aiming to drive awareness of recurrent pericarditis.


Research and Development Focus



  • Pipeline:

  • Consists of several product candidates across various stages of development with a robust focus on immune modulation for conditions with significant unmet needs.

  • Collaborations and partnerships in place to extend the reach and capabilities in developing transformative therapies.


  • Disease Registries:

  • Initiated RESONANCE Patient Registry aimed at better understanding and managing recurrent pericarditis.


Future Outlook



Kiniksa Pharmaceuticals has shown a strong commitment to developing innovative treatments for immunological and inflammatory diseases. Their robust pipeline and strategic partnerships indicate potential future growth and impact in the biopharmaceutical sector, further emphasizing their dedication to addressing critical unmet medical needs.



This report synthesizes available information on Kiniksa Pharmaceuticals based on data provided. Some fields lack specific data and are thus annotated accordingly.